Renal Cancer - Results from #5020

Programmed death-1 (PD-1) receptor/PD-1 ligand (PD-L1) expression in fumarate hydratase-deficient renal cell carcinoma August 25, 2017

Predictive role of PD-L1 expression in the response of renal Medullary carcinoma to PD-1 inhibition August 25, 2017

Prognostic DNA methylation markers for renal cell carcinoma: a systematic review August 25, 2017

Microvascular and lymphovascular tumor invasion are associated with poor prognosis and metastatic spread in renal cell carcinoma: A validation study in clinical practice August 25, 2017

The Risk of Tumour Recurrence in Patients Undergoing Renal Transplantation for End-stage Renal Disease after Previous Treatment for a Urological Cancer: A Systematic Review August 25, 2017

Neoadjuvant therapy for localized and locally advanced renal cell carcinoma August 25, 2017

Stereotactic ablative radiation therapy in renal cell carcinoma: From oligometastatic to localized disease August 24, 2017

Response to single agent PD-1 inhibitor after progression on previous PD-1/PD-L1 inhibitors: a case series August 24, 2017

Cost Effectiveness of Nivolumab in Advanced Renal Cell Carcinoma August 23, 2017

Primary collision tumors of the kidney composed of oncocytoma and papillary renal cell carcinoma: A review August 23, 2017

Expression of long non-coding RNA MFI2-AS1 is a strong predictor of recurrence in sporadic localized clear-cell renal cell carcinoma August 22, 2017

Perinephric and Sinus Fat Invasion in Stage pT3a Tumors Managed by Partial Nephrectomy August 22, 2017

Phase I dose-escalation study of pazopanib combined with bevacizumab in patients with metastatic renal cell carcinoma or other advanced tumors August 22, 2017

[German S3 guideline for renal cell carcinoma : Presentation and discussion of essential aspects for the radiation oncologist] August 21, 2017

Identification and validation of soluble carrier family expression signature for predicting poor outcome of renal cell carcinoma August 21, 2017

Nephroblastoma overexpressed gene expression and its prognostic implications of clinical outcomes in renal cell carcinoma patients August 18, 2017

Early skeletal muscle loss during target therapy is a prognostic biomarker in metastatic renal cell carcinoma patients August 18, 2017

Commentary on: "An integrated metabolic atlas of clear cell renal cell carcinoma." Hakimi AA, Reznik E, Lee CH, Creighton CJ, Brannon AR, Luna A, Aksoy BA, Liu EM, Shen R, Lee W, Chen Y, Stirdivant SM, Russo P, Chen YB, Tickoo SK, Reuter VE, Cheng EH, San August 18, 2017

Comparison of efficacy, safety, and quality of life between sorafenib and sunitinib as first-line therapy for Chinese patients with metastatic renal cell carcinoma August 18, 2017

Partial nephrectomy for T3aN0M0 renal cell carcinoma: shall we step forward? August 17, 2017

Page 252 of 457